Delphine Diagnostics Showcases AI Innovations at BioNJ’s 2024 AI & Digital Health Day

Hoboken, NJ. November 18, 2024

Delphine Diagnostics is proud to announce its participation in the 2nd Annual AI & Digital Health Day, hosted by BioNJ on November 18, 2024, at Stevens Institute of Technology in Hoboken, NJ. This event brought together industry leaders to explore the latest trends in artificial intelligence and digital health within the life sciences sector.

Our CEO, Andy Bala, delivered a presentation highlighting Delphine Diagnostics’ advancements in AI-driven diagnostic solutions. He discussed how our technologies are enhancing patient outcomes and streamlining healthcare processes.

The event featured rapid-fire lightning pitches from entrepreneurial companies revolutionizing healthcare through AI-driven innovations. Attendees also had the opportunity to engage with experts from financial, legal, investor, and healthcare provider organizations at Industry Help Desks.

We are honored to have been part of this dynamic program and remain committed to advancing AI and digital health innovations that improve patient care.

For more information about the event, please visit BioNJ’s official page here.

Delphine Diagnostics partners with Rutgers Business School on an impactful project

New Brunswick, NJ. July 2024: 

As a part of the Industry Client Project course at Rutgers Business School, Delphine Diagnostics has been working with talented students looking to make a real-world impact in the Biotechnology and Medical Devices space. It has been great to offer this opportunity for collaboration and to gather valuable and actionable insights.

The Delphine Team worked closely with the students to provide guidance and mentorship throughout the semester. Alfred D’lorio (CFO), Andy Bala (CEO),  and Mary Stack (Scientist) took the lead on this project.

Jesse Chao, PharmD is a pharmacist who has nearly 10 years of experience in the biopharmaceutical industry. He started his career in Pharmacovigilance/Risk Management and eventually transitioned to clinical development. He is currently a clinical scientist at Regeneron Pharmaceuticals working on allergy/immunology drug development. He anticipates completion of the MBA program at Rutgers Business School in August 2024.

Emily O’Neill, PharmD, RPh is a pharmacist with five years of experience in the Pharmaceutical Industry. She started her career as a postdoctoral fellow with Rutgers/Bristol Myers Squibb and is now a Cardiovascular Pricing and Access Strategy Lead at Bristol Myers Squibb. Emily is in her final semester of the MBA program at Rutgers Business School.

Jaime Rochotte is in the Masters of Supply Chain Analytics Program at Rutgers Business School and has almost 8 years of experience in the logistics industry. She is currently an Inventory Control Analyst at BevDS analyzing inventory levels and recording and reporting the variety pack production done on-site.

A big thank you to Professor Joe Agresta for his constant support. Wishing these students the very best of luck and bright futures ahead!

 

Delphine Diagnostics presents at Wireless World Research Forum

Glassboro, NJ. June 2024:

Andy Bala, Delphine DX’s Founder and CEO, was invited to speak at the Wireless World Research Forum at Rowan University on June 19th, 2024, as a part of the session for “Advancing Global Communication: The Role of AI in Shaping the Future of Technology”, chaired by Professor Nidhal Carla Bouaynaya.

The talk titled “The Role of AI in Medical Diagnostics” was very well received. The attendees had several great questions and asked for clarifications regarding scenarios related to false positive and false negative prediction outcomes of AI-based models in hospital settings. The presentation also highlighted the benefits to patient outcomes and reduced hospital stay durations.

Learn more at:
💠 https://wwrf51.wwrf.ch/

Delphine Diagnostics CEO at ‘Entrepreneurs Exchange’

Princeton, NJ. June 2024: 

In the words of our CEO, Andy Bala:

“I’m happy to have attended a valuable event, ‘Entrepreneurs Exchange’, at Princeton, New Jersey, last week. I want to share my gratitude for Debbie Hart and her team at BioNJ; a big thank you to Kristin Roosevelt and her Thermo Fisher Scientific team, and Elizabeth Rowley along with her team from Princeton Innovation Center BioLabs. It was truly a great opportunity to learn and network with fellow entrepreneurs and supporters of Delphine Diagnostics.”

Follow us to keep up with the latest developments in the diagnostics space.

 

 

Delphine Diagnostics well represented at the Princeton Tech Meetup

Princeton, NJ. January 2024: Andy Bala, CEO of Delphine Diagnostics, attended the Princeton Tech Meetup focused on Artificial Intelligence in Healthcare.

Some of the key takeaways are:

  1. Artificial intelligence-based solutions have recently gained traction in pharma drug discovery, clinical trials, hospital health networks, and product manufacturing. Faster adoption led to better outcomes in business process efficiencies, improved patient outcomes (risk predictions, guidance for surgery planning,  improved patient outcomes (such as social determinants, and value-based care for seniors), and of course, financials – Better Operating margin improvements ensuring that the health of the Hospital Health Networks stay robust.
  2. Responding to a volley of questions from participants, the panelists shared insights on how to solve complex challenges such as bias in data leading to bias in Artificial Intelligence models, and how to improve the accuracy of AI models which could be due to lack of a relevant and real dataset to train models.
  3. The panel recommended using a governance committee framework with Scientists, Clinicians, Ethics, Compliance, D&I, and the board. The panel also recommended developing and using a responsible Artificial Intelligence model development framework.

 

We would like to thank Venu Moola and Chris Boroski for the great work done in selecting this much-needed topic and managing the Princeton Tech Meetup.This very engaging panel with such relevant insights would not have been possible without a great panel comprising of Donna Conroy – CEO SciMar ONE, Kash Patel – EVP & CDIO Hackensack Meridian Health, and Rohit Vashisht – CEO WhizAI. Lastly, many thanks Jim Barrood, CEO of Innovation+, who enabled effective interaction among the participants and panelists.

Delphine is proud to be a part of this rapidly growing area of Health Tech!